Texas MPN Workshop 2022 | Insights into the MANIFEST-2 study
Claire Harrison
• 24 Aug 2022
In this video, Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares some insights into the ongoing Phase III MANIFEST-2 study (NCT04603495) comparing the use of pelabresib plus ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis (MF). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
